MedVector
OperatingMedVector Corp
Biotech · El Segundo, CA · Founded 2017
Transforming Clinical Trials
Financials
FY2018–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round. Dashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth, so don't compare them with the other bars.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Share counts as of Dec 31, 2019| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common Stock | 5,000,245 | 1 | 100.0% | $1.45Nov 2020 |
Principal holders% as the filing states it, Jul 23, 2025
- Scott Stout55.3%of votes
Sold to the crowd
- Reg CF · Nov 2020602,955 shares at $1.45$874.3K· 555 investors
- Reg CF · May 2024Common Stock$114.6K· 60 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
6 people
An established healthcare innovator, named one of the Most Influential Healthcare Leaders in 2021 and recognized by Marquis’ Who’s Who in 2024, Scott brings financial expertise from Morgan Stanley where he aided several startups on their capital structures and go-to-market strategies. He excels at strategic direction, team building, and securing capital.
Craig Lipset leads at the forefront of innovation in clinical research and medicine development. He is an advisor to technology and biopharmaceutical companies, leading universities, and the venture community and was the Head of Clinical Innovation and Venture Partner at Pfizer. He continues to be one of the leading industry voices of decentralized clinical trials and innovation.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 5 of 6 annual reports (FY2020–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 18 filings on EDGAR- Form D/AMay 6, 20260001820902-26-000006EDGAR
- Form DOct 16, 20250001820902-25-000010EDGAR
- Form C-ARJul 23, 20250001820902-25-000004EDGAR
- Form C-ARJul 23, 20250001820902-25-000005EDGAR
- Form C-TRJul 23, 20250001820902-25-000006EDGAR
- Form C-ARMay 29, 20250001820902-25-000002EDGAR
- Form C-USep 13, 20240001665160-24-001309EDGAR
- Form CMay 21, 20240001665160-24-000884EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.